ArticleCureus2025
Unusual Stroke-Like Presentation of Tumefactive Multiple Sclerosis in a 27-Year-Old Man.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumefactive multiple sclerosis (TMS) is a rare subtype of multiple sclerosis with diverse clinical presentations, often leading to delays in diagnosis and treatment initiation. On investigation, it presents with a large (>2 cm) demyelinating mass-like lesion and can be accompanied by ring enhancement, perilesional edema, and mass effect. We report the case of a 27-year-old man who presented with right-sided weakness and numbness. He had a similar presentation one year ago without a definitive diagnosis. Computed tomography (CT) of the brain showed multiple bilateral hypodensities and vasogenic edema. Magnetic resonance imaging (MRI) of the brain revealed multifocal lesions with partial ring enhancement, which prompted further investigations. Laboratory studies and cerebrospinal fluid (CSF) analysis returned negative for infectious and autoimmune etiologies. Spinal MRI identified focal, non-enhancing lesions in the spinal cord, supporting a demyelinating process. The patient was diagnosed with TMS and received five days of IV methylprednisolone, resulting in significant improvement. This case highlights the importance of clinical suspicion of TMS, which can mimic other etiologies. It also shows the role of efficient history-taking in obviating the need for brain biopsy, which is usually done for similar cases exposing the patient to unwarranted adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.